Its turnover grew 11.5%, to nearly RON1.1 billion.
“It was a difficult year, full of challenges and tense for most of us. From the first signals at local level, we realized that it will not be something transient, so we mobilized, worked on several scenarios and adapted to the new conditions,” said Mihai Marcu, president and CEO of MedLife.
The company launched new screening programs for patients with chronic diseases, as well as Covid testing, researched natural immunization for COVID 19, virus sequencing or antibody dynamics after infection and post vaccine.
“We are ready to capture the revenues that will come from the post-pandemic recovery period,” Marcu added.
In the fourth quarter of 2020, MedLife reported a turnover of RON316 million, from RON256 million in the fourth quarter of 2019, and posted a net profit of RON18.2 million from a loss of RON1.4 million in the year-earlier period.
The medical services provider plans to further consolidate its position on the Romanian market and possibly expand in the region.
“We have credit lines that are dedicated both to M&A program and the development of projects aimed at recovering the post-COVID patient, having at our disposal the new increase, amounting to EUR20 million, plus cash generated by our business divisions. At the same time, we will continue, gradually, the development of the MedLife Medical Park project, which has the potential to become in the next period the most complex medical project in Romania and will be easily compared with other large medical entities in Europe. The new investments and acquisitions will be carefully calibrated according to the evolution of the pandemic,” said Marcu.